Trial
NCT02667496
Safety Study of Sargramostim in Treating Patients With Mild Cognitive Impairment Due to Alzheimer's Disease
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Sanofi
Collaborators
National Institute on Aging (NIA)
Condition
Dementia Alzheimer's Type
Intervention
Sargramostim GZ402664
Why stopped
Slow recruitment
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-04-07